BACKGROUND Bacillus Calmette-Guérin (BCG) is taken into account a promising dwell bacterial supply system. Nonetheless, a number of proposals for rBCG vaccines haven’t progressed, primarily because of the limitations of the accessible expression techniques. OBJECTIVES To acquire a set of mycobacterial vectors utilizing a spread of promoters with completely different strengths based mostly on a typical spine, beforehand proven to be steady. METHODS Mycobacterial expression vectors based mostly on the pLA71 vector as spine, have been obtained inserting completely different promoters (PAN, PαAg, PHsp60, PBlaF* and PL5) and the inexperienced fluorescence protein (GFP) as reporter gene, to judge options equivalent to their relative strengths, and the in vitro (inside macrophages) and in vivo stability.
FINDINGS The relative fluorescence noticed with the completely different vectors confirmed growing energy of the promoters: PAN was the weakest in each Mycobacterium smegmatis and BCG and PBlaF* was larger than PHsp60 in BCG. The relative fluorescence noticed in a macrophage cell line confirmed that PBlaF* and PHsp60 have been comparable. It was not doable to acquire strains reworked with the extrachromosomal expression vector containing the PL5 in both species. MAIN CONCLUSION We have now obtained a set of doubtless steady mycobacterial vectors with a prepare of expression ranges, for use within the growth of rBCG vaccines.
Building of E. coli-Mycobacterium shuttle vectors with a wide range of expression techniques and polypeptide tags for gene expression in mycobacteria.
Cloning and expression of a desired gene is indispensable in molecular biology research. Expression vectors, on this regard, ought to supply a lot wanted flexibility and selection of cloning methods for each in vivo and in vitro protein expression experiments. Moreover, availability of possibility to select from varied reporter tags permits one to be versatile throughout designing of an experiment in a extra related method. Thus, the necessity of a flexible expression system can’t be ignored. Though a number of completely different expression vectors can be found for gene expression in mycobacteria, they lack the required versatility of expression and the inclusion of reporter tags.
We right here current the development of a set of 9 E. coli-Mycobacterium shuttle plasmids, which provide a mix of three mycobacterial promoter techniques (warmth shock inducible-hsp60, tetracycline-, and acetamide-inducible) together with three polypeptide tags (Inexperienced Fluorescent Protein (GFP), Glutathione S-transferase (GST) and hexa-histidine tag). These vectors supply the cloning of a goal gene in all of the 9 given vectors in parallel, thus permitting the era of recombinant plasmids that may categorical the goal gene from completely different promoters with completely different tags. Right here, whereas the hexa-histidine and GST tags can be utilized for protein purification and pull-down experiments, the GFP-tag can be utilized for protein localization throughout the cell. Moreover, the vectors additionally supply the selection of positioning of the reporter tag both on the N-terminus or on the C-terminus of the expressed protein, which is achieved by cloning of the gene at any of the 2 blunt-end restriction enzyme websites accessible within the vector.
We consider that these plasmids will probably be extraordinarily helpful within the gene expression research in mycobacteria by providing the alternatives of promoters and reporters. Our work additionally paves the way in which to creating extra such plasmids with different tags and promoters which will discover use in mycobacterial biology.
Characterisation of Alternative Expression Vectors for Recombinant Bacillus Calmette-Guérin as Live Bacterial Delivery Systems
PDGFB-expressing mesenchymal stem cells enhance human hematopoietic stem cell engraftment in immunodeficient mice.
The bone marrow (BM) area of interest regulates a number of hematopoietic stem cell (HSC) processes. Medical remedy for hematological malignancies by HSC transplantation usually requires preconditioning by way of whole physique irradiation, which severely and irreversibly impairs the BM area of interest and HSC regeneration. Novel methods are wanted to reinforce HSC regeneration in irradiated BM. We in contrast the results of EGF, FGF2, and PDGFB on HSC regeneration utilizing human mesenchymal stem cells (MSCs) that have been transduced with these components by way of lentiviral vectors. Among the many above area of interest components examined, MSCs transduced with PDGFB most importantly improved human HSC engraftment in immunodeficient mice. PDGFB-MSC-treated BM enhanced transplanted human HSC self-renewal in secondary transplantations extra effectively than GFP-transduced MSCs. Gene set enrichment evaluation confirmed elevated antiapoptotic signaling in PDGFB-MSCs in contrast with GFP-MSCs.
exhibited enhanced survival and growth after transplantation, leading to an enlarged humanized area of interest cell pool that present a greater humanized microenvironment to facilitate superior engraftment and proliferation of human hematopoietic cells. Our research show the efficacy of \ in supporting human HSC engraftment. In vitro evaluation reveals that 60% of DCs was contaminated by this vector whereas the infectivity of different management adenoviral vectors was lower than 10%, demonstrating superior infectivity on DCs.
Filter Paper Simple 110mm - PK100 |
|||
| FIL0122 | Scientific Laboratory Supplies | PK100 | EUR 8.1 |
Filter Paper Simple 125mm - PK100 |
|||
| FIL0124 | Scientific Laboratory Supplies | PK100 | EUR 9.45 |
Filter Paper Simple 150mm - PK100 |
|||
| FIL0126 | Scientific Laboratory Supplies | PK100 | EUR 12.15 |
Blunt Simple Cloning Kit |
|||
| 20-abx098060 | Abbexa |
|
|
Blunt Simple Cloning Kit |
|||
| abx098060-100l | Abbexa | 100 µl | EUR 737.5 |
Blunt Simple Cloning Kit |
|||
| abx098060-1ml | Abbexa | 1 ml | Ask for price |
Blunt Simple Cloning Kit |
|||
| abx098060-200l | Abbexa | 200 µl | EUR 950 |
pUC57- Simple- gRNA backbone |
|||
| PVT11371 | Nova Lifetech | 2ug | EUR 215 |
pUC57 Simple-PVT1 Plasmid |
|||
| PVTB00511 | Nova Lifetech | 2ug | EUR 288 |
pUC57 Simple-Pdcd4 Plasmid |
|||
| PVTB70003 | Nova Lifetech | 2ug | EUR 288 |
Simple add on polarizer - EACH |
|||
| MIC5830 | Scientific Laboratory Supplies | EACH | EUR 62.28 |
Filter Paper Simple 90mm - PK100 |
|||
| FIL0120 | Scientific Laboratory Supplies | PK100 | EUR 6.75 |
Fast, Simple & Efficient Cloning Kit without competent cell |
|||
| GWB-PS10F8 | GenWay Biotech | 20reactions | Ask for price |
Fast, Simple & Efficient Cloning Kit without competent cell |
|||
| GWB-PSEBB3 | GenWay Biotech | 40reactions | Ask for price |
Fast, Simple & Efficient Cloning Kit without competent cell |
|||
| GWB-6F5A1D | GenWay Biotech | 100reactions | Ask for price |
Fast, Simple & Efficient Cloning Kit without competent cell |
|||
| GWB-768936 | GenWay Biotech | 10reactions | Ask for price |
SiMPLe Protein Labeling Kit (Sortase Mediated Protein Ligation) |
|||
| 79392 | BPS Bioscience | 3 units of Sortase | EUR 560 |
|
Description: Sortases catalize a transpeptidation reaction, where the enzyme cleaves the amide bond between the threonine and glycine of the sortase recognition sequence (LPXTG for S. aureus Sortase A), generating a thioacyl intermediate. Subsequently, this intermediate is resolved by the N-terminus of an oligoglycine nucleophile, creating a new peptide bond that links the substrate to the incoming nucleophile. The Sortagging Kit takes advantage of this reaction to label virtually any recombinant antibody or protein containing the sortase recognition sequence. Labeling efficiency of greater than 90% is achieved by taking advantage of the highly active Sortase 5Δ Pentamutant. Simply combine your protein of interest with Sortase 5Δ and a polyglycine label, and incubate for 1 hour at 37°C. Purification columns are included to remove Sortase 5Δ and excess label. The kit also includes Ubiquitin-LPETGH6 and GGG-Clover as positive controls._x000D_ |
|||
OASA05978-1ML - Herpes Simple Virus 1/2 Antibody - HRP Conjugated |
|||
| OASA05978-1ML | Aviva Systems Biology | 1ml | EUR 499 |
Simple Cyanide Standard for Ion Chromatography and Calibration of Ion Selective Electrodes - 500ML |
|||
| RSCN9-2X | Scientific Laboratory Supplies | 500ML | EUR 168.75 |
Simple Cyanide Standard for Ion Chromatography and Calibration of Ion Selective Electrodes - 125ML |
|||
| RSCN9-2Y | Scientific Laboratory Supplies | 125ML | EUR 108 |
Blood Genomic DNA Extraction Mini Kit (50prep), (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK-001 | Favorgen | 50 preps | EUR 180 |
Blood Genomic DNA Extraction Mini Kit (100prep), (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK-001-1 | Favorgen | 100 preps | EUR 232.8 |
Blood Genomic DNA Extraction Mini Kit (300prep), (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK-001-2 | Favorgen | 300 preps | EUR 406.8 |
Blood Genomic DNA Extraction MAXI Kit (10prep) (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK-003 | Favorgen | 10 preps | EUR 242.4 |
Blood Genomic DNA Extraction MAXI Kit (24prep) (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK-003-1 | Favorgen | 24 preps | EUR 379.2 |
Blood Genomic DNA Extraction Mini Kit (50prep), (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK_001 | Favorgen | 1 kit | EUR 39.5 |
Blood Genomic DNA Extraction Mini Kit (100prep), (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK_001-1 | Favorgen | 1 kit | EUR 73 |
Blood Genomic DNA Extraction Mini Kit (300prep), (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK_001-2 | Favorgen | 1 kit | EUR 269 |
Blood Genomic DNA Extraction MAXI Kit (10prep) (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK_003 | Favorgen | 1 kit | EUR 80 |
Blood Genomic DNA Extraction MAXI Kit (24prep) (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK_003-1 | Favorgen | 1 kit | EUR 170 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (AP) |
|||
| MBS6424835-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (AP) |
|||
| MBS6424835-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (APC) |
|||
| MBS6424836-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (APC) |
|||
| MBS6424836-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (FITC) |
|||
| MBS6424838-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (FITC) |
|||
| MBS6424838-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (HRP) |
|||
| MBS6424839-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (HRP) |
|||
| MBS6424839-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (PE) |
|||
| MBS6424845-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (PE) |
|||
| MBS6424845-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (Biotin) |
|||
| MBS6424837-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (Biotin) |
|||
| MBS6424837-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
Blood / Cultured Cells Genomic DNA Extraction Midi Kit (25prep) (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK-002 | Favorgen | 25 preps | EUR 241.2 |
Blood / Cultured Cells Genomic DNA Extraction Midi Kit (25prep) (With Proteinase K Powder, for wide applications and simple procedure) |
|||
| FABGK_002 | Favorgen | 1 kit | EUR 78.5 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 405) |
|||
| MBS6424840-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 405) |
|||
| MBS6424840-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 490) |
|||
| MBS6424841-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 490) |
|||
| MBS6424841-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 550) |
|||
| MBS6424842-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 550) |
|||
| MBS6424842-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 650) |
|||
| MBS6424843-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 650) |
|||
| MBS6424843-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 750) |
|||
| MBS6424844-01mL | MyBiosource | 0.1mL | EUR 950 |
LITAF (LPS-induced TNF-alpha Factor, Lipopolysaccharide-induced Tumor Necrosis Factor-alpha Factor, PIG7, SIMPLE, TP53I7) (MaxLight 750) |
|||
| MBS6424844-5x01mL | MyBiosource | 5x0.1mL | EUR 4120 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) |
|||
| MBS627980-1mL | MyBiosource | 1mL | EUR 640 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) |
|||
| MBS627980-5x1mL | MyBiosource | 5x1mL | EUR 2740 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (PE) |
|||
| MBS6263059-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (PE) |
|||
| MBS6263059-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (PE) |
|||
| MBS6263060-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (PE) |
|||
| MBS6263060-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (AP) |
|||
| MBS6260508-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (AP) |
|||
| MBS6260508-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (AP) |
|||
| MBS6260509-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (AP) |
|||
| MBS6260509-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (HRP) |
|||
| MBS629906-1mL | MyBiosource | 1mL | EUR 770 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (HRP) |
|||
| MBS629906-5x1mL | MyBiosource | 5x1mL | EUR 3310 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (FITC) |
|||
| MBS6262038-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (FITC) |
|||
| MBS6262038-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (FITC) |
|||
| MBS6262039-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (FITC) |
|||
| MBS6262039-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (HRP) |
|||
| MBS6262548-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (HRP) |
|||
| MBS6262548-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (HRP) |
|||
| MBS6262549-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (HRP) |
|||
| MBS6262549-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (APC) |
|||
| MBS6261019-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (APC) |
|||
| MBS6261019-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (APC) |
|||
| MBS6261020-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (APC) |
|||
| MBS6261020-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (Biotin) |
|||
| MBS6261530-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (Biotin) |
|||
| MBS6261530-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (Biotin) |
|||
| MBS6261531-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (Biotin) |
|||
| MBS6261531-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 490) |
|||
| MBS6264081-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 490) |
|||
| MBS6264081-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 490) |
|||
| MBS6264082-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 490) |
|||
| MBS6264082-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 550) |
|||
| MBS6264592-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 550) |
|||
| MBS6264592-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 550) |
|||
| MBS6264593-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 550) |
|||
| MBS6264593-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 650) |
|||
| MBS6265103-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 650) |
|||
| MBS6265103-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 650) |
|||
| MBS6265104-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 650) |
|||
| MBS6265104-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 750) |
|||
| MBS6265614-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 750) |
|||
| MBS6265614-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 750) |
|||
| MBS6265615-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 750) |
|||
| MBS6265615-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 405) |
|||
| MBS6263570-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 405) |
|||
| MBS6263570-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 405) |
|||
| MBS6263571-01mL | MyBiosource | 0.1mL | EUR 795 |
Herpes Simplex Virus I, II (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) (MaxLight 405) |
|||
| MBS6263571-5x01mL | MyBiosource | 5x0.1mL | EUR 3435 |
LITAF (Lipopolysaccharide-induced TNF factor, CMT1C, FLJ38636, MGC116698, MGC116700, MGC116701, MGC125274, MGC125275, MGC125276, PIG7, SIMPLE, TP53I7, LPS-induced TNF-alpha factor) |
|||
| MBS608501-01mL | MyBiosource | 0.1mL | EUR 525 |
LITAF (Lipopolysaccharide-induced TNF factor, CMT1C, FLJ38636, MGC116698, MGC116700, MGC116701, MGC125274, MGC125275, MGC125276, PIG7, SIMPLE, TP53I7, LPS-induced TNF-alpha factor) |
|||
| MBS608501-5x01mL | MyBiosource | 5x0.1mL | EUR 2205 |
Herpes Simplex Virus I, II, Glycoprotein D (HSV I, II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) |
|||
| MBS609964-01mg | MyBiosource | 0.1mg | EUR 680 |
Herpes Simplex Virus I, II, Glycoprotein D (HSV I, II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) |
|||
| MBS609964-5x01mg | MyBiosource | 5x0.1mg | EUR 2905 |
Herpes Simplex Virus I, II, Glycoprotein B (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) |
|||
| MBS633581-01mg | MyBiosource | 0.1mg | EUR 725 |
Herpes Simplex Virus I, II, Glycoprotein B (HSV I,II, Herpes Simplex Virus 1, HSV1, Herpes Simplex Virus 2, HSV2) |
|||
| MBS633581-5x01mg | MyBiosource | 5x0.1mg | EUR 3100 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) |
|||
| MBS655123-1mL | MyBiosource | 1mL | EUR 480 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) |
|||
| MBS655123-5x1mL | MyBiosource | 5x1mL | EUR 1930 |
Herpes Simplex Virus II (HSV II, Herpes Simplex Virus 2, HSV2) |
|||
| MBS655190-02mL | MyBiosource | 0.2mL | EUR 865 |
Herpes Simplex Virus II (HSV II, Herpes Simplex Virus 2, HSV2) |
|||
| MBS655190-5x02mL | MyBiosource | 5x0.2mL | EUR 3680 |
Herpes Simplex Virus II (HSV II, Herpes Simplex Virus 2, HSV2) |
|||
| MBS655237-1mL | MyBiosource | 1mL | EUR 480 |
Herpes Simplex Virus II (HSV II, Herpes Simplex Virus 2, HSV2) |
|||
| MBS655237-5x1mL | MyBiosource | 5x1mL | EUR 1930 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) |
|||
| MBS655274-02mL | MyBiosource | 0.2mL | EUR 865 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) |
|||
| MBS655274-5x02mL | MyBiosource | 5x0.2mL | EUR 3680 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) (PE) |
|||
| MBS6263058-01mL | MyBiosource | 0.1mL | EUR 1025 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) (PE) |
|||
| MBS6263058-5x01mL | MyBiosource | 5x0.1mL | EUR 4460 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) (AP) |
|||
| MBS6260507-01mL | MyBiosource | 0.1mL | EUR 1025 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) (AP) |
|||
| MBS6260507-5x01mL | MyBiosource | 5x0.1mL | EUR 4460 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) (HRP) |
|||
| MBS6262547-01mL | MyBiosource | 0.1mL | EUR 1025 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) (HRP) |
|||
| MBS6262547-5x01mL | MyBiosource | 5x0.1mL | EUR 4460 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) (APC) |
|||
| MBS6261018-01mL | MyBiosource | 0.1mL | EUR 1025 |
Herpes Simplex Virus I (HSV I, Herpes Simplex Virus 1, HSV1) (APC) |
|||
| MBS6261018-5x01mL | MyBiosource | 5x0.1mL | EUR 4460 |
Furthermore, a mean of 14% of DCs have been contaminated by , whereas lower than 3% of non-DCs have been contaminated following in vivo administration, demonstrating extremely selective in vivo DC an infection. Importantly, vaccination with this car expressing human glioma-specific antigen, reveals a chronic survival profit in GL261CMV-IE-implanted murine glioma fashions (p < 0.0007). Moreover, when rechallenged, cancerous cells have been fully rejected. In conclusion, our novel, viral-mediated, DC-based immunization strategy has the numerous therapeutic potential for sufferers with high-grade gliomas.